Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pyxis Oncology, Inc. PYXS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.67
+292.4%

Pyxis Oncology, Inc. (PYXS) is a Biotechnology company in the Healthcare sector, currently trading at $1.70. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is PYXS = $7 (+292.4% upside).

Valuation: PYXS trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25).

Financials: revenue is $14M, -14.2%/yr average growth. Net income is $80M (loss), growing at +9.9%/yr. Net profit margin is -574.5% (negative). Gross margin is 82.8% (-14.3 pp trend).

Balance sheet: total debt is $19M against $53M equity (Debt-to-Equity (D/E) ratio 0.35, conservative). Current ratio is 3.41 (strong liquidity). Debt-to-assets is 20.4%. Total assets: $92M.

Analyst outlook: 7 / 9 analysts rate PYXS as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).

$6.67
▲ 292.35% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Pyxis Oncology, Inc., the average price target is $6.67, with a high forecast of $8.00, and a low forecast of $5.00.
Highest Price Target
$8.00
Average Price Target
$6.67
Lowest Price Target
$5.00

PYXS SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PYXS

✓
VALUE Pass
100/100
PYXS trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25). Forward PEG -0.64 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $7, implying +311.8% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
40/100
PYXS: -14.2%/yr revenue is, +9.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet PYXS: Debt-to-Equity (D/E) ratio 0.35 (conservative), Current ratio is 3.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
PYXS: Gross margin is 82.8% (-14.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 7 / 9 analysts rate PYXS as buy (78%). Analyst consensus target is $7 (+311.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
PYXS: Net profit margin is -574.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.833-5.55
Volume565.44K
Avg Volume (30D)452K
Market Cap$106.81M
Beta (1Y)1.42
Share Statistics
EPS (TTM)-1.28
Shares Outstanding$62.14M
IPO Date2021-10-08
Employees44
CEOThomas Civik
Financial Highlights & Ratios
Revenue (TTM)$13.86M
Gross Profit$11.47M
EBITDA$-79.91M
Net Income$-79.62M
Operating Income$-84.42M
Total Cash$66.86M
Total Debt$18.67M
Net Debt$3.25M
Total Assets$91.52M
Price / Earnings (P/E)-1.3
Price / Sales (P/S)7.71
Analyst Forecast
1Y Price Target$7.00
Target High$8.00
Target Low$5.00
Upside+311.8%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 22% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS7473241013

Price Chart

Track all markets on TradingView
PYXS
Pyxis Oncology, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.83 52WK RANGE 5.55

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.25
+0.53%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
 MREO
MREO
Mereo BioPharma Group plc
$0.33
+2.81%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.20
+1.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message